Recent advancements in molecular targeted therapy have exploited the discovery of distinct cancer subsets with epidermal growth factor receptor (EGFR) mutations and led to a major paradigm shift in the treatment of NSCLC [1, 2]. This evidence concerns the gene EGFR and cancer.